---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005329"
form_type: "8-K"
ticker: "AMRN"
cik: "0000897448"
company_name: "AMARIN CORP PLCUK"
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T19:40:41.985743+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amarin Q4 2022 net income $0.9M; revenue down 38% YoY; positive free cash flow $4M

## Summary
- Q4 2022 net product revenue $89.5M, down 38% YoY; U.S. revenue stabilized at $88.0M vs $87.9M in Q3.
- GAAP net income $0.9M ($0.00 EPS); non-GAAP adjusted net income $7.3M ($0.02 EPS).
- Positive free cash flow of $4M in Q4; cost savings program on track to exceed $100M target.
- European expansion: VAZKEPA launched in 5 markets, pricing negotiations in 5 more; peak revenue potential $1B+ in Europe.
- International: 6 regulatory approvals in 2022, plus New Zealand in Jan 2023; license agreement with CSL Seqirus for Australia/NZ.

## SEC filing metadata
- accession: 0000950170-23-005329
- form_type: 8-K
- ticker: AMRN
- cik: 0000897448
- company_name: AMARIN CORP PLCUK
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/897448/000095017023005329/0000950170-23-005329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/897448/000095017023005329/amrn-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005329
- JSON: https://secwatch.observer/filing/0000950170-23-005329.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005329.txt

## Key facts
- Earnings Releases
  AMARIN CORP PLCUK reported the three months ended December 31, 2022 results: revenue $90.2 million, net income $0.9 million, EPS $0.00 per share.
  - Period: the three months ended December 31, 2022
  - Revenue: $90.2 million
  - Net income: $0.9 million
  - EPS: $0.00 per share
  - Result: reported results
  source text: Financial Update Total net revenue for the three months ended December 31, 2022 was $90.2 million, compared to $144.5 million in the corresponding period of 2021, a decrease of 38%. Net product revenue for the three months ended December 31, 2022 was $89.5 million, compared to $143.7 million in the corresponding period of 2021, a decrease of 38%. This decrease was driven primarily by a decrease in volume of VASCEPA sales to Amarin’s customers in the United States, which were adversely impacted by generic availability in the United States. USA net product revenue was $88.0 million for Q4 2022 compared to $87.9 million in Q3 2022. Amarin recognized licensing and royalty revenue of approximately $0.7 million and $0.8 million during the three months ended December 31, 2022 and 2021, respectively, from VASCEPA-related commercial sales from our partners in Canada, the China region and the Middle East. Cost of goods sold for the three months ended December 31, 2022 was $26.6 million, compared
  evidence_url: https://www.sec.gov/Archives/edgar/data/897448/000095017023005329/0000950170-23-005329-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.